(125 days)
Not Found
No
The summary describes a system for electroanatomical mapping and visualization, focusing on tracking catheters, acquiring electrical signals, and displaying maps. There is no mention of AI, ML, or related concepts in the device description, intended use, or performance studies. The performance studies focus on traditional verification and validation methods and animal/clinical studies without mentioning AI/ML specific evaluation metrics or methodologies.
No
The device is described as a mapping system that visualizes and displays information within the heart, rather than directly treating a disease or condition. It is used for diagnosis and planning, not therapy.
Yes
The device is described as a "mapping system" that allows "real-time visualization of intra-cardiac catheters" and "display of cardiac maps." It also states that "acquired patient signals, including body surface ECG and intra-cardiac electrograms, may also be recorded and displayed." Furthermore, it is designed for "electroanatomical mapping" to "display electroanatomical maps" including "activation maps, voltage maps and fractionation maps." These functions are used to identify and understand the electrical activity and structure of the heart, which is a diagnostic purpose to identify areas for treatment.
No
The device description and performance studies explicitly mention hardware components and hardware verification and validation, indicating it is not a software-only device.
Based on the provided information, the Rhythmia Mapping System is not an In Vitro Diagnostic (IVD).
Here's why:
- Intended Use: The intended use clearly states "catheter based atrial and ventricular mapping." This involves using a device inside the body to gather information about the heart's electrical activity and structure.
- Device Description: The description details tracking catheters inside the heart, visualizing their location, and constructing geometric shells and electroanatomical maps based on intra-cardiac information.
- Nature of the Data: The system acquires and displays "intra-cardiac electrograms" and "body surface ECG." These are physiological signals measured directly from or on the patient's body, not from samples taken from the body (like blood, urine, or tissue) that would be analyzed in vitro.
IVD devices are designed to examine specimens derived from the human body (like blood, urine, tissue, etc.) outside of the body to provide information for diagnostic purposes. The Rhythmia Mapping System operates in vivo (within the living body).
N/A
Intended Use / Indications for Use
The Rhythmia Mapping System and accessories are indicated for catheter based atrial and ventricular mapping. The mapping system allows real-time visualization of intra-cardiac catheters as well as display of cardiac maps in a number of different formats. The acquired patient signals, including body surface ECG and intra-cardiac electrograms, may also be recorded and displayed on the system's display screen.
Product codes (comma separated list FDA assigned to the subject device)
DQK
Device Description
The Rhythmia Mapping System and accessories are designed for electroanatomical mapping and is able to simultaneously acquire data from multiple electrodes. The Rhythmia Mapping System tracks catheters inside the heart in order to visualize their location and construct geometric shells. The Rhythmia Mapping System is also capable of using intra-cardiac location and electrical information to display electroanatomical maps - electrical activity information on the constructed geometry. Such electrical information can be visualized in 3D in color. The Rhythmia Mapping System can display various types of electroanatomical maps including geometrical shell only, activation maps, voltage maps and fractionation maps.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
intra-cardiac
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
In vitro testing: Bench tests performed by the company included software verification and validation and hardware verification and validation. The test results demonstrate that the Rhythmia Mapping System meets the requirements in the applicable standards and specifications, and is substantially equivalent to the legally marketed predicate device.
In vivo testing: Design validation was performed in a GLP animal study using a swine model. The Rhythmia Mapping System was used to determine the system's ability to record and display intracardiac electrograms, share intracardiac and ECG signal with recording system, route stimulator signal, create geometrical shells, create activation maps, create voltage maps, accurately track the position of the Rhythmia Mapping Catheter, and accurately track the position of third party catheters. The Rhythmia Mapping System worked as intended and there were no safety issues identified.
Clinical experience: A clinical evaluation was performed outside the US with 33 subjects. There were no adverse events related to the Rhythmia Mapping System, and the System performed as intended.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
CARTO 3 EP Navigation System (K072202), EnSite System Model EE3000 (K070902)
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 870.1425 Programmable diagnostic computer.
(a)
Identification. A programmable diagnostic computer is a device that can be programmed to compute various physiologic or blood flow parameters based on the output from one or more electrodes, transducers, or measuring devices; this device includes any associated commercially supplied programs.(b)
Classification. Class II (performance standards).
0
K130750
5 510(k) Summary
| General Information | ||
|---|---|---|
| · Date | ||
| Compiled | March 15, 2013 | JUL 2 2 2013 |
| Classification | Class II, 21 CFR § 870.1425, Programmable Diagnostic Computer, Product | |
| Code DQK | ||
| Trade Name | Rhythmia Mapping System | |
| Model | ||
| Number | The Rhythmia Mapping System is comprised of several components, see form | |
| 3514 Section F for complete details. The model numbers of the main | ||
| components include: M004RH1000 0 through M004RH4400 0. | ||
| Submitter | Rhythmia Medical, Inc. | |
| 111 South Bedford Street, Suite 205 | ||
| Burlington, MA 01803 | ||
| Contact | Leon Amariglio | |
| Rhythmia Medical, Inc. | ||
| 111 S Bedford St. | ||
| Suite 205 | ||
| Burlington, MA 01803 | ||
| Phone: 617-591-9191 | ||
| Fax: 617-449-9513 |
Indications for Use
The Rhythmia Mapping System and accessories are indicated for catheter based atrial and ventricular mapping. The mapping system allows real-time visualization of intra-cardiac catheters as well as display of cardiac maps in a number of different formats. The acquired patient signals, including body surface ECG and intra-cardiac electrograms, may also be recorded and displayed on the system's display screen.
1
Predicate Device
CARTO 3 EP Navigation System (K072202)
Manufactured by Biosense Webster, Inc.
EnSite System Model EE3000 (K070902)
Manufactured by St. Jude Medical
Device Description
The Rhythmia Mapping System and accessories are designed for electroanatomical mapping and is able to simultaneously acquire data from multiple electrodes. The Rhythmia Mapping System tracks catheters inside the heart in order to visualize their location and construct geometric shells. The Rhythmia Mapping System is also capable of using intra-cardiac location and electrical information to display electroanatomical maps - electrical activity information on the constructed geometry. Such electrical information can be visualized in 3D in color. The Rhythmia Mapping System can display various types of electroanatomical maps including geometrical shell only, activation maps, voltage maps and fractionation maps.
Testing
In vitro testing was performed on the Rhythmia Mapping System to assure reliable design and performance. The bench tests performed by the company included software verification and validation and hardware verification and validation. The test results demonstrate that the Rhythmia Mapping System meets the requirements in the applicable standards and specifications, and is substantially equivalent to the legally marketed predicate device.
In vivo testing
Design validation of the system was performed in a GLP animal study. The Rhythmia Mapping System was used in a swine model to determine the system's ability to record and display intracardiac electrograms, share intracardiac and ECG signal with recording system, route stimulator signal, create geometrical shells, create activation maps, create voltage maps, accurately track the position of the Rhythmia Mapping Catheter, and accurately track the position of third party catheters. The Rhythmia Mapping System worked as intended and there were no safety issues identified.
Clinical experience
A clinical evaluation was performed outside the US using the Rhythmia Mapping System. Thirty-three (33) subjects were included in the studies using the Rhythmia Mapping System. There were no adverse events related to the Rhythmia Mapping System, and the System performed as intended.
2
Summary of Substantial Equivalence
Rhythmia Medical believes the Rhythmia Mapping System and accessories are substantially equivalent to the predicate products. The indications for use, intended use, product function, design and materials used, are either identical or substantially equivalent to existing legally marketed predicate products.
·
3
Image /page/3/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a stylized eagle with three tail feathers, representing the department's mission to protect the health of all Americans and provide essential human services. The eagle is surrounded by the words "DEPARTMENT OF HEALTH & HUMAN SERVICES • USA" in a circular arrangement.
Public Health Service
Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-002
July 22, 2013
Rhythmia Medical, Inc. C/O Mr. Leon Amariglio 111 South Bedford St Suite 205 Burlington, MA 01803 US
Re: K130750
Trade/Device Name: Rhythmia mapping system Regulation Number: 21 CFR 870.1425 Regulation Name: Programmable Diagnostic Computer Regulatory Class: Class II Product Code: DQK Dated: June 7, 2013 Received: June 10, 2013
Dear Mr. Leon Amariglio:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you; however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act
4
Page 2 - Leon Amariglio
or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Small Manufacturers, International and Consumer Assistance at its tollfree number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638 2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.
Sincerely yours,
Owen P. Faris -S
- for Bram D. Zuckerman, Ph.D. Director
· Division of Cardiovascular Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
5
K130750
4 Indications for Use Statement
510(k) Number (if known): This application Device Name: Rhythmia Mapping System Indications for Use: The Rhythmia Mapping System and accessories are indicated for catheter based atrial and ventricular mapping. The mapping system allows real-time visualization of intra-cardiac catheters as well as display of cardiac maps in a number of different formats. The acquired patient signals, including body surface ECG and intra-cardiac electrograms, may also be recorded and displayed on the system's display screen.
Prescription Use X (Per 21 CFR 801 Subpart D)
Over-The-Counter Use (Per 21 CFR 801 Subpart C)
PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)
AND/OR
Concurrence of CDRH, Office of Device Evaluation (ODE)
Digitally signed by
Owen P. Faris -S
Date: 2013.07.22
14:19:01 -04'00'
DC000-148 Rev. 01
Page 30 of 85